News & Updates

In a recent study, seliciclib therapy demonstrates its potential in reversing hypercortisolism by directly targeting pituitary corticotrophs in Cushing disease (CD). However, the agent is associated with liver toxicity, which is resolved by withdrawing treatment.

Treatment with tyrosine kinase inhibitors (TKIs), such as sunitinib, provides survival benefits to patients with metastatic pheochromocytomas/paragangliomas (PPGLs), suggests a recent study.

Among people with nonalcoholic fatty liver disease (NAFLD), those who are lean appear to be at higher risk of death than their overweight and obese counterparts despite having fewer metabolic comorbidities, a study has shown.

Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.

For patients with hypertension and diabetes, longer time spent in blood pressure (BP) target range helps lower the risk of cardiovascular disease, according to a study.

A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).

In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.

Carnitine appears to be beneficial in the treatment of women with polycystic ovary syndrome (PCOS), with the drug helping improve ovulation, clinical pregnancy, insulin resistance, and body mass index, according to the results of a meta-analysis.

Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.